Methyltestosterone: Clinical Trials

11 trials of Methyltestosterone, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

3 completed, 3 terminated, 2 active not recruiting, 1 not yet recruiting. 6 Phase 2, 2 Early Phase 1, 2 Phase 1, 1 Phase 3, 1 Phase 4.

By phase and status

PhaseTrialsStatus
Phase 26Completed 2, Terminated 2, Not yet recruiting 1, Recruiting 1
Early Phase 12Completed 1, Terminated 1
Phase 12Active not recruiting 2
Phase 31Not yet recruiting 1
Phase 41Unknown 1

Follow Methyltestosterone: new trials by email Literature Review of Methyltestosterone trials Research Report on Methyltestosterone

Trials newest first · largest first

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Testing the Use of High Dose Testosterone Followed by Darolutamide Compared to the Usual Care for Patients With Metastatic Prostate Cancer
Abiraterone Acetate, Biospecimen Collection, Bone Scan - Metastatic Castration-Resistant Prostate Adenocarcinoma, Stage IVB Prostate Cancer AJCC v8
Phase 2 / Phase 3Not yet recruitingECOG-ACRIN Cancer Research Group4322027-01-062026-10-01
Bipolar Androgen Therapy to Restore Sensitivity to Androgen Deprivation Therapy for Patients With Metastatic Castration Resistant Prostate Cancer
Biopsy, Bone Scan, Computed Tomography - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Carcinoma
Phase 1Active not recruitingRoswell Park Cancer Institute32024-12-192026-08-07
Supraphysiological Androgen to Enhance Treatment Activity in Metastatic Castration-Resistant Prostate Cancer, SPECTRA Study
Biopsy Procedure, Biospecimen Collection, Bone Scan - Castration-Resistant Prostate Carcinoma, Metastatic Prostate Adenocarcinoma
Phase 2RecruitingUniversity of Washington692024-05-212026-07-21
Perioperative Testosterone Replacement Therapy for the Improvement of Post-Operative Outcomes in Patients With Low Testosterone
Best Practice, Quality-of-Life Assessment, Questionnaire Administration - Hypogonadism, Malignant Urinary System Neoplasm
Phase 1Active not recruitingEmory University562021-01-252026-05-26
Mechanisms of Hypertension in Women With Polycystic Ovary Syndrome
GnRH antagonist, GnRH antagonist + MethylTESTOSTERone 5 MG - Polycystic Ovary Syndrome, Hypertension
Early Phase 1TerminatedYale University282017-12-012024-02-02
Compromised Microcirculation in Women With Polycystic Ovary Syndrome
ganirelix acetate, methyl testosterone - Polycystic Ovary Syndrome
Early Phase 1CompletedYale University282008-02-012016-07-04
Comparison of Estrogen and Methyltestosterone Combination Treatments for Postmenopausal Hot Flushes
Esterified Estrogens (EE) and Methyltestosterone (MT) - Hot Flushes, Menopause, Postmenopause
Phase 2CompletedSolvay Pharmaceuticals12512005-06-012008-08-15
Testosterone Replacement in Middle-Aged Hypogonadal Men With Dysthymia: Parallel Group, Double Blind Randomized Trial
Testoviron - Dysthymic Disorder
Phase 4UnknownSheba Medical Center2004-09-012006-10-04
The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Hysterectomized Postmenopausal Women
esterified estrogens 1.25mg and methyltestosterone 2.5mg, Esterified estrogens 1.25 mg - Menopause
Phase 2TerminatedSolvay Pharmaceuticals1332004-07-012008-04-11
The Efficacy of ESTRATEST® Tablets in Relieving Menopausal Symptoms in Estrogenized, Non-Hysterectomized Postmenopausal Women
esterified estrogens 1.25 mg and methyltestosterone 2.5 mg, Esterified estrogens 1.25 mg - Menopause
Phase 2TerminatedSolvay Pharmaceuticals282004-07-012008-04-11
Study of the Efficacy of ESTRATEST® H.S. Tablets in Relieving Menopausal Symptoms in Estrogenized Postmenopausal Women
esterified estrogens 0.625 mg and methyltestosterone 1.25 mg - Menopause
Phase 2CompletedSolvay Pharmaceuticals3502004-06-012015-01-16

Conditions studied

Prostatic Neoplasms (3)  ·  Polycystic Ovary Syndrome (2)  ·  Dysthymic Disorder (1)  ·  Hot Flashes (1)  ·  Hypertension (1)  ·  Hypogonadism (1)  ·  Urologic Diseases (1)  ·  Urologic Neoplasms (1)

Sponsors

Solvay Pharmaceuticals (4)  ·  Yale University (2)  ·  ECOG-ACRIN Cancer Research Group (1)  ·  Emory University (1)  ·  Roswell Park Cancer Institute (1)  ·  Sheba Medical Center (1)  ·  University of Washington (1)

Countries

United States (9)  ·  Canada (1)  ·  Israel (1)  ·  Russia (1)

Top investigators

Michael Schweizer (2)  ·  Nina Stachenfeld, PhD (2)  ·  Guy Orr, MD (1)  ·  Kenneth Ogan, MD (1)  ·  Saby George, MD (1)

Results publications

PMID 42294856

NIH funding

2005 (1), P30CA138292 (1), P50CA097186 (1), R01HL135089 (1), R21HL093450 (1), U10CA180820 (1)